Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 12;24(24):17383.
doi: 10.3390/ijms242417383.

Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape

Muftah Mahmud  1 , Swati Vasireddy  2 , Krisstina Gowin  3 , Akshay Amaraneni  3
Affiliations
Review

Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape

Muftah Mahmud et al. Int J Mol Sci. .

Abstract

Myelofibrosis (MF), Myeloproliferative neoplasms (MPNs), and MDS/MPN overlap syndromes have a broad range of clinical presentations and molecular abnormalities, making their diagnosis and classification complex. This paper reviews molecular aberration, epigenetic modifications, chromosomal anomalies, and their interactions with cellular and other immune mechanisms in the manifestations of these disease spectra, clinical features, classification, and treatment modalities. The advent of new-generation sequencing has broadened the understanding of the genetic factors involved. However, while great strides have been made in the pharmacological treatment of these diseases, treatment of advanced disease remains hematopoietic stem cell transplant.

Keywords: MDS-MPN; molecular and mutational landscape; primary myelofibrosis; secondary myelofibrosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Primary (a) and secondary myelofibrosis (b).
Figure 2
Figure 2
Distribution of Major Driver Mutation and Triple Negative Disease.
Figure 3
Figure 3
Intersectional relationship of MDS/MPN.
See this image and copyright information in PMC

References

    1. Dameshek W. Some speculations on the myeloproliferative syndromes [editorial]. Blood. 1951;6(4):372-375. Blood. 2016;127:663. doi: 10.1182/blood.V6.4.372.372. - DOI - PubMed
    1. Gangat N., Tefferi A. Myelofibrosis biology and contemporary management. Br. J. Haematol. 2020;191:152–170. doi: 10.1111/bjh.16576. - DOI - PubMed
    1. Rampal R., Al-Shahrour F., Abdel-Wahab O., Patel J.P., Brunel J.P., Mermel C.H., Bass A.J., Pretz J., Ahn J., Hricik T., et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123:e123–e133. doi: 10.1182/blood-2014-02-554634. - DOI - PMC - PubMed
    1. Verstovsek S., Yu J., Kish J.K., Paranagama D., Kaufman J., Myerscough C., Grunwald M.R., Colucci P., Mesa R. Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States. Ann. Hematol. 2020;99:2555–2564. doi: 10.1007/s00277-020-04055-w. - DOI - PMC - PubMed
    1. Tefferi A., Saeed L., Hanson C.A., Ketterling R.P., Pardanani A., Gangat N. Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis. Leukemia. 2017;31:2851–2852. doi: 10.1038/leu.2017.268. - DOI - PMC - PubMed

MeSH terms